Episode # 320 • 31 Jul 2026
Gem-iDRS for BCG Unresponsive Bladder Cancer: A Deep Dive
Can a drug-eluting bladder device change the treatment algorithm for BCG-unresponsive non–muscle invasive bladder cancer (NMIBC)? In this episode of BackTable Urology, Dr. Ruchi Talwar interviews Dr. Sarah Psutka to explore the emerging role of a novel intravesical device that delivers sustained gemcitabine therapy for patients refusing or ineligible for cystectomy. They highlight new FDA-approved treatment options, real-world workflow considerations, and the clinical potential for continuous intravesical chemotherapy in a crowded therapeutic landscape.
This podcast is supported by
Timestamps
00:00 - Introduction
02:40 - Why Focus on TAR-200
05:35 - Device Basics
07:05 - Dosing Schedule Explained
11:17 - SUNRISE-01 Trial Results
15:07 - Patient Selection and Contraindications
20:52 - Indications for Device Removal
23:26 - Clinic Workflow Learning Curve
25:56 - Tips for Insertion and Device Deployment
28:52 - Cystoscopy Findings and Surveillance Protocol
32:16 - Treatment Sequencing
38:43 - Future Trial and Research Directions
45:16 - Biomarkers, AI, and Personalizing Care
46:35 - Cost, Supportive Care, and Patient Burden
48:42 - Closing Thoughts
You may also like
More about this episode
The conversation dives into patient selection, preparation, and side effect management for TAR-200, as well as the key findings from the SUNRISE-01 trial. Dr. Psutka discusses dosing schedules, when to remove the device, and how to handle complications like UTI, hematuria, and LUTS. The episode also covers surveillance protocols, the impact on clinic operations, and the importance of balancing vigilant cancer surveillance with patient burden. Finally, they touch on future directions, including biomarkers, AI-assisted pathology, and optimizing the timing of cystectomy and supportive care for a more personalized approach to NMIBC.
The Materials available on BackTable are provided for informational and educational purposes only and are not a substitute for the independent professional judgment of a qualified healthcare professional in diagnosing or treating patients. Any opinions, statements, or views expressed are those of the individual contributors and do not necessarily reflect those of the publisher, platform, or any affiliated organization.